Effective drug delivery system for duchenne muscular dystrophy using hybrid liposomes including gentamicin along with reduced toxicity

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 5, 2011, Pages 712-716

  Yukihara, Mamiko ^a   Ito, Kaori ^b   Tanoue, Osamu ^a   Goto, Koichi ^a   Matsushita, Taku ^a   Matsumoto, Yoko ^a   Masuda, Masako ^b   Kimura, Shigemi ^b   Ueoka, Ryuichi ^a  

^a SOJO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Duchenne muscular dystrophy; Gentamicin; Hybrid liposome; X chromosome linked muscular distrophy mouse

Indexed keywords

CREATINE KINASE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; DYSTROPHIN; GENTAMICIN; HYBRID LIPOSOME; POLIDOCANOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG MUSCLE LEVEL; DRUG RETENTION; DUCHENNE MUSCULAR DYSTROPHY; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HYDRODYNAMICS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OTOTOXICITY; PARTICLE SIZE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; GENTAMICINS; LIPOSOMES; MALE; MICE; MICROSCOPY, CONFOCAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 79955660280     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.712     Document Type: Article

References (29)

1. Hoffman E. P., Brown R. H. Jr., Kunkel L. M., Cell, 51, 919-928 (1987).
2. Koenig M., Hoffman E. P., Bertelson C. J., Monaco A. P., Feener C., Kunkel L. M., Cell, 50, 509-517 (1987).
3. Gillard E. F., Chamberlain J. S., Murphy E. G., Duff C. L., Smith B., Burghes A. H. M., Thompson M. W., Sutherland J., Oss I., Bodrug S. E., Klamut H. J., Ray P. N., Worton R. G., Am. J. Hum. Genet., 45, 507-520 (1989).
4. Forrest S. M., Cross G. S., Flint T., Speer A., Robson K. J., Davies K. E., Genomics, 2, 109-114 (1988).
5. Lindlöf M., Kiuru A., Kääriäinen H., Kalimo H., Lang H., Pihko H., Rapola J., Somer H., Somer M., Savontaus M. L., de la Chapelle A., Am. J. Hum. Genet., 44, 496-503 (1989).
6. Prior T. W., Wenger G. D., Papp A. C., Snyder P. J., Sedra M. S., Bartolo C., Moore J. W., Highsmith W. E., Hum. Mutat., 5, 263-268 (1995).
7. Mendell J. R., Buzin C. H., Feng J., Yan J., Serrano C., Sangani D. S., Wall C., Prior T. W., Sommer S. S., Neurology, 57, 645-650 (2001).
8. Howard M., Frizzell R. A., Bedwell D. M., Nat. Med., 2, 467-469 (1996).
9. Howard M. T., Shirts B. H., Petros L. M., Flanigan K. M., Gesteland R. F., Atkins J. F., Ann. Neurol., 48, 164-169 (2000).
10. Barton-Davis E. R., Cordier L., Shoturma D. I., Leland S. E., Sweeney H. L., J. Clin. Invest., 104, 375-381 (1999).
11. Welch E. M., Barton E. R., Zhuo J., Tomizawa Y., Friesen W. J., Trifillis P., Paushkin S., Patel M., Trotta C. R., Hwang S., Wilde R. G., Karp G., Takasugi J., Chen G., Jones S., Ren H., Moon Y. C., Corson D., Turpoff A. A., Campbell J. A., Conn M. M., Khan A., Almstead N. G., Hedrick J., Mollin A., Risher N., Weetall M., Yeh S., Branstrom A. A., Colacino J. M., Babiak J., Ju W. D., Hirawat S., Northcutt V. J., Miller L. L., Spatrick P., He F., Kawana M., Feng H., Jacobson A., Peltz S. W., Sweeney H. L., Nature (London), 447, 87-91 (2007).
12. PTC THERAPEUTICS. "Ataluen for Genetic Disorders." 〈http://www.ptcbio.com/3.1.1-genetic-disorders.aspx〉.
13. Ueoka R., Moss R. A., Swarup S., Matsumoto Y., Strauss G., Murakami Y., J. Am. Chem. Soc., 107, 2185-2186 (1985).
14. Ueoka R., Matsumoto Y., Moss R. A., Swarup S., Sugii A., Harada K., Kikuchi J., Murakami Y., J. Am. Chem. Soc., 110, 1588-1595 (1988).
15. Kitamura I., Kochi M., Matsumoto Y., Ueoka R., Kuratsu J., Ushio Y., Cancer Res., 56, 3986-3992 (1996).
16. Matsumoto Y., Kato T., Suzuki H., Hirose S., Naiki Y., Hirashima M., Ueoka R., Bioorg. Med. Chem. Lett., 10, 2617-2619 (2000).
17. Tanaka Y., Goto K., Matsumoto Y., Ueoka R., Int. J. Pharm., 359, 264-271 (2008).
18. Matsumoto Y., Kato T., Iseki S., Suzuki H., Nakano K., Iwahara M., Ueoka R., Bioorg. Med. Chem. Lett., 9, 1937-1940 (1999).
19. Ueoka R., Matsumoto Y., Ichihara H., Kiyokawa T., "Chemotherapy with Hybrid Liposomes Composed of Dimyristoylphosphatidylcholine and Polyoxyethylenealkyl Ether without Drugs," ACS Symposium Series 830, Biological Systems Engineering, Chap. 14, ed. by Marten M. R., Park T. H., Nagamune T., Am. Chem. Soc. Books, Washington, 2002, pp. 177-189.
20. Matsumoto Y., Iwamoto Y., Matsushita T., Ueoka R., Int. J. Cancer, 115, 377-382 (2005).
21. Ichihara H., Nagami H., Kiyokawa T., Matsumoto Y., Ueoka R., Anticancer Res., 28, 1187-1196 (2008).
22. Komizu Y., Matsumoto Y., Ueoka R., Bioorg. Med. Chem. Lett., 16, 6131-6134 (2006).
23. Nakashima K., Miyagi M., Goto K., Matsumoto Y., Ueoka R., Yakugaku Zasshi, 124, 231-235 (2004).
24. Nakano K., Iwamoto Y., Takata W., Matsumoto Y., Ueoka R., Bioorg. Med. Chem. Lett., 12, 3251-3254 (2002).
25. Hakuba N., Koga K., Gyo K., Usami S., Tanaka K., J. Neurosci., 20, 8750-8753 (2000).
26. Williams J. H., Schray R. C., Sirsi S. R., Lutz G. J., BMC Biotechnol., 8, 35-47 (2008).
27. Gregorevic P., Blankiship M. J., Allen J. M., Crawford R. W., Meuse L., Miller D. G., Russell D. W., Chamberlain J. S., Nat. Med., 10, 828-834 (2004).
28. Allen T. M., Hansen C., Martin F., Redemann C., Yau-Young A., Biochem. Biophys. Acta, 1066, 29-36 (1991).
29. Ichihara H., Nagami H., Yamamoto K., Matsumoto Y., Ueoka R., Yakugaku Zasshi, 123, 25-34 (2003).